Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

被引：224
作者：
Kerr, K. M. [1 ,2 ]
Bubendorf, L. [3 ]
Edelman, M. J. [4 ]
Marchetti, A. [5 ]
Mok, T. [6 ]
Novello, S. [7 ]
O'Byrne, K. [8 ,9 ]
Stahel, R. [10 ]
Peters, S. [11 ]
Felip, E. [12 ]
机构：
[1] Aberdeen Royal Infirm, Dept Pathol, Aberdeen, Scotland
[2] Aberdeen Univ Med Sch, Aberdeen, Scotland
[3] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
[4] Univ New Mexico Canc Ctr, Albuquerque, NM USA
[5] Univ Fdn, Ctr Predict Mol Med, Ctr Excellence Ageing, Chieti, Italy
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[7] Univ Turin, Azienda Osped Univ San Luigi Orbassano, Dept Oncol, Thorac Oncol Unit, I-10124 Turin, Italy
[8] Trinity Coll Dublin, Dublin, Ireland
[9] Queensland Univ Technol, Brisbane, Qld 4001, Australia
[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland
[11] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
[12] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷 / 09期
关键词：
ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations; MESSENGER-RNA EXPRESSION; IN-SITU HYBRIDIZATION; EXTERNAL QUALITY ASSESSMENT; FACTOR RECEPTOR MUTATIONS; ALK GENE REARRANGEMENTS; EML4-ALK FUSION GENE; PHASE-III TRIAL; BRONCHIAL BIOPSY; INTERNATIONAL-ASSOCIATION; HISTOLOGICAL CLASSIFICATION;
D O I：
10.1093/annonc/mdu145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
引用
收藏
页码：1681 / 1690
页数：10
相关论文
共 50 条
[31]   Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group [J].
Chang, Sunhee ;
Shim, Hyo Sup ;
Kim, Tae Jung ;
Choi, Yoon-La ;
Kim, Wan Seop ;
Shin, Dong Hoon ;
Kim, Lucia ;
Park, Heae Surng ;
Lee, Geon Kook ;
Lee, Chang Hun .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2021, 55 (03) :181-191
[32]   Molecular Targets in the Treatment of Non-Small-Cell Lung Cancer: Is There Hope on the Horizon? [J].
Carter, Corey A. ;
Nations, Joel Anthony ;
Lazarus, Angeline .
POSTGRADUATE MEDICINE, 2014, 126 (07) :139-148
[33]   LncRNAs in Non-Small-Cell Lung Cancer [J].
Ginn, Lucy ;
Shi, Lei ;
La Montagna, Manuela ;
Garofalo, Michela .
NON-CODING RNA, 2020, 6 (03)
[34]   Immunotherapy for non-small-cell lung cancer [J].
Thomas, Anish ;
Jakopovic, Marko .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) :1061-1064
[35]   Staging of Non-Small-Cell Lung Cancer [J].
Akhurst, Tim .
PET CLINICS, 2018, 13 (01) :1-+
[36]   Non-Small-Cell Lung Cancer: Then and Now [J].
Schiller, Joan H. ;
Gandara, David R. ;
Goss, Glenwood D. ;
Vokes, Everett E. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :981-983
[37]   Ifosfamide in non-small-cell lung cancer [J].
Rosell, R ;
Martin, C ;
Balaña, C .
ANNALS OF ONCOLOGY, 1999, 10 :25-28
[38]   Canadian consensus: oligoprogressive , pseudoprogressive, and oligometastatic non-small-cell lung cancer [J].
Laurie, S. A. ;
Banerji, S. ;
Blais, N. ;
Brule, S. ;
Cheema, P. K. ;
Cheung, P. ;
Daaboul, N. ;
Hao, D. ;
Hirsh, V ;
Juergens, R. ;
Laskin, J. ;
Leighl, N. ;
MacRae, R. ;
Nicholas, G. ;
Roberge, D. ;
Rothenstein, J. ;
Stewart, D. J. ;
Tsao, M. S. .
CURRENT ONCOLOGY, 2019, 26 (01) :E81-E93
[39]   Third CECOG consensus on the systemic treatment of non-small-cell lung cancer [J].
Brodowicz, T. ;
Ciuleanu, T. ;
Crawford, J. ;
Filipits, M. ;
Fischer, J. R. ;
Georgoulias, V. ;
Gridelli, C. ;
Hirsch, F. R. ;
Jassem, J. ;
Kosmidis, P. ;
Krzakowski, M. ;
Manegold, Ch. ;
Pujol, J. L. ;
Stahel, R. ;
Thatcher, N. ;
Vansteenkiste, J. ;
Minichsdorfer, C. ;
Zoechbauer-Mueller, S. ;
Pirker, R. ;
Zielinski, C. C. .
ANNALS OF ONCOLOGY, 2012, 23 (05) :1223-1228
[40]   Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin [J].
Oser, Matthew G. ;
Niederst, Matthew J. ;
Sequist, Lecia V. ;
Engelman, Jeffrey A. .
LANCET ONCOLOGY, 2015, 16 (04) :E165-E172
12345